Singapore O&G 1H 2020 results: The good and the bad

Singapore O&G (SOG) reported a decent set of 1H 2020 results despite the COVID-19 pandemic in Singapore. Revenue fell 4% to SGD17.8 million while net profit fell 21% to SGD3.7 million Here's the good and the bad about Singapore O&G results. Good Let's start with the good. Singapore O&G reinstated their dividend (0.5 cents). The … Continue reading Singapore O&G 1H 2020 results: The good and the bad

Singapore O&G: 6 things to note in the 2019 annual report

Am I the only SOG shareholder who has given up looking at the share price?  Anyway, here's are six key highlights from their 2019 annual report. Let's start with the bad news: Dermatology impairment Increasing competition and weak medical tourism trends in Singapore resulted in a SGD11.3 million goodwill impairment for the year. Excluding the … Continue reading Singapore O&G: 6 things to note in the 2019 annual report

Zero sales test

How long can a company survive with zero revenue?  The COVID-19 crisis has forced governments to restrict movement so  restaurants, hotels and travel companies are faced with a grim scenario where revenue drops to zero. The cyclical companies in my portfolio such as China Aviation  Oil, TripAdvisor and HRNet are vulnerable but I subjected all … Continue reading Zero sales test

2019 year in review and most popular posts

This year was a tough year for my portfolio with 4 out of 6 stocks in the portfolio posting negative returns since I wrote about them.   Date purchased Start Now Dividend return (%) Capital return (%) Total return iFAST 22-Apr-18 0.92 1.03 7% 12% 19% Kingsmen 29-Apr-18 0.59 0.45 8% -24% -15% SOG 3-Jun-18 … Continue reading 2019 year in review and most popular posts

Portfolio review: Q3 2019 review

The five SGX companies in my portfolio reported mixed Q3 2019 results and their share prices have been depressed.These five companies should deliver growth in the future so I'm happy to hold these companies. iFAST and SOG has been the most consistent performers in terms of revenue and net profit growth and it's a painful … Continue reading Portfolio review: Q3 2019 review

SOG: Delivering growth

Singapore O&G (SOG) is a healthcare company focusing on specialist practices such as obstetrics, dermatology, gynae-oncology, and paediatrics. SOG was incorporated in 2011 and listed on the SGX in 2015 with 7 doctors. Since its IPO, SOG has grown headcount mainly through doctor recruitment rather than acquisitions. The company’s only acquisition to date involved the … Continue reading SOG: Delivering growth

Portfolio review: Q1 2019 results

All five Evergreen stocks (iFAST, Kingsmen, SOG, China Aviation Oil and HRNet) reported poor results for the first quarter of 2019 but I'm sticking with them. These companies have a history of producing great results and I'm giving them 2-3 years more before I consider selling. iFAST Revenue and net profit declined because of "a … Continue reading Portfolio review: Q1 2019 results

SOG: Winning market share for 5th consecutive year

SOG’s cancer and O&G doctors gained recognition and won market share in 2018. SOG is one of my favourite medical stocks on the SGX. Their share of the private birth market grew for the fifth consecutive year. Based on their 2018 annual report, SOG specialists delivered 1,824 babies in 2018 which works out to a … Continue reading SOG: Winning market share for 5th consecutive year